Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Part of paid clinical trials in Loma Linda, California.
- Sponsor
- Loma Linda University
- Study ID
- NCT04097158
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Sample Collection — OTHERThe investigators will be collecting blood, urine, and spinal fluid samples.
Study Details
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.
Key Dates
- Start date
- Oct 8, 2019
- Status verified
- Jun 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 160 participants (estimated)
Arms
- Arm: Upper Motor Neuron predominant ALS
- Arm: Lower Motor Neuron predominant ALS
- Arm: Bulbar predominant ALS
- Arm: Generalized ALS
Primary Outcome Measure
Define pharmacodynamic biomarkers of oxidative stress and antioxidant capacity in different ALS/MND phenotypes. [ Time Frame: 6 months ]
Central Contacts
- Imran Qasim(909) 558-2037
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Loma Linda University | Loma Linda | California | 92354 | Jeffrey Rosenfeld, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Loma Linda, CA
Related Studies
- BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With TetraplegiaRecruiting · Leigh R. Hochberg, MD, PhD. · Sacramento, California
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsPHASE3 · Recruiting · AB Science · Birmingham, Alabama
- Clinical Procedures to Support Research in ALSRecruiting · University of Miami · Irvine, California
- HEALEY ALS Platform Trial - Master ProtocolPHASE2/PHASE3 · Recruiting · Merit E. Cudkowicz, MD · Phoenix, Arizona